This is an HTML version of an attachment to the Freedom of Information request 'Stakeholder contacts on Japan-EU Free Trade Agreement (JEFTA)'.






Ref. Ares(2017)1802316 - 04/04/2017
Ref. Ares(2017)3028981 - 16/06/2017
Art. 4.1(b) From: 
Sent: 
28 July 2014 15:33 
To: 
 (TRADE); 

(TRADE); 
 (TRADE); 
 (TRADE); 
 (GROW); 
 (TRADE);
Earlier today 
 met with 2 representatives of Cosmetics Europe 
 to discuss their concerns in relation to the Japanese market in view 
of putting together a second list of NTBs. In preparation to the meeting, we have received the enclosed 
position paper: 
Cosmetics Europe indicated to us the following order of priorities: 
1) Increased transparency and harmonisation of regulations on ingredients in cosmetics/quasi drugs
2) Compatibility of requirements between the different categories of products (cosmetics vs. quasi drugs)
3) Acceptance of chemical substances already approved under REACH Regulations by Japan
4) Acceptance of validated alternative methods to animal testing
5) Simplification of complicated and time consuming cosmetic import process
6) Less restrictive approach to efficacy claims (the industry is aware that this is rather unlikely to happen)
Art. 4.1(a)
3rd indent,
4.2 
1st indent
Cosmetics Europe agreed to provide more specific data in order to substantiate better their requests 
especially in relation to Point 1 (more detailed data will be provided on the regulatory approach in Japan 
and in the EU and specific examples of products concerned), Point 2 (list of examples will be provided), 
Point 4 (description of the alternative methods to animal testing will be submitted), Point 5 (specification of 
the most difficult steps in the import process will be provided). 
Art. 4.1(b) After the meeting, 
 to look into the exchange of letters with Korea that put an 
end to the TBR case on cosmetics and to see whether any of the solutions found back then could be of 
use with Japan. 
Finally, it is to be discussed 
 whether issues that are not new (such as those concerning the 
cosmetics industry), but are being brought by business only at this rather late stage should be considered 
for the second list of NTBs. I believe that this was not the initial intention behind the second NTBs list, but 
in case the issues are well substantiated could be considered.